Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield MI Prior Auth & Step Therap…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentblue cross blue shield - michiganPolicy N/A

    Medicare Plus Blue Group prior authorization and step therapy criteria (Formulary PA/ST Program 2026)

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Medicare Plus Blue Group prior authorization and step therapy requirements for prescription drugs included in the 2026 formulary for Blue Cross Blue Shield of Michigan; affects prescribers and pharmacies submitting PA/ST requests for covered Part D medications.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyMedicare Plus Blue Group prior authorization and step therapy criteria (Formulary PA/ST Program 2026)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of diagnosis and required prior therapy trials or lab/test results as specified for the requested product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026plan year
    391total pages
    Medicare Plus Blueplan(s) governed
    1 Yeartypical coverage duration
    Somerequires prior Part D drug
    Recurringcombination biologic exclusion

    Coverage Criteria (Product-specific)

    inv-01: Adbry (dupilumab biosimilar/brand-specific criteria)

    Coverage is provided when ALL of the following product-specific criteria are met:

    Adbry initial eligibility: Patient is >= 12 years of age with a diagnosis of moderate to severe atopic dermatitis and has had a trial and treatment failure of ONE of: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil.age >= 12 years

    Prerequisite Part D drug required; prior therapies must be documented

    Combination restriction: Request does not involve concurrent use of Adbry with another biologic or targeted DMARD indicated for the same condition.

    Combination biologic use is excluded

    Dosing and reauthorization: Reauthorization requires documentation of positive clinical response to therapy. For patients <100 kg who achieve response after 16 weeks, dosage is limited to 300 mg every 4 weeks unless clinical rationale is provided to exceed this limit.
    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyMedicare Plus Blue Group prior authorization and step therapy criteria (Formulary PA/ST Program 2026)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of diagnosis and required prior therapy trials or lab/test results as specified for the requested product.
    SourceLink
    On This Page
    Coverage Criteria (Product-specific)Step Therapy RequirementsProvider Actions & Documentation RequirementsCoding, Lab Thresholds & MeasurablesInitial Therapy CriteriaContinuation / Reauthorization CriteriaSite of Care / Part B vs Part D DeterminationBackground & ScopeDefinitions and Terms

    Document clinical response and weight-based dosing rationale where applicable

    inv-02: Braftovi coverage conditions

    Coverage is provided when ANY of the following indication- and mutation-specific conditions are met:

    Braftovi - melanoma (BRAF V600E/V600K): Unresectable or metastatic melanoma with documented BRAF V600E or V600K mutation AND trial of vemurafenib plus cobimetinib OR combination use with binimetinib as specified.presence of BRAF V600E or V600K mutation

    Mutation status and prior therapy must be documented

    Braftovi - metastatic colorectal cancer (BRAF V600E): Initial treatment of metastatic CRC with documented BRAF V600E mutation requires combination with cetuximab and fluorouracil‑based chemotherapy; for treatment after prior therapy, requires combination with cetuximab.presence of BRAF V600E mutation

    Document prior therapies and mutation status

    Braftovi - NSCLC (BRAF V600E): Metastatic NSCLC with documented BRAF V600E mutation when used in the required combination regimens as specified in product labeling.presence of BRAF V600E mutation

    Document mutation status and combination regimen

    inv-03: Oncology/specialty prerequisite therapy

    Coverage for listed oncology and specialty agents is provided when ALL specified prerequisite therapy or combination requirements for the indicated disease are satisfied:

    Oncology/specialty prerequisite therapies: Patient has received the prior therapies or will receive the combination regimens required by the specific product and indication (examples include trials of Calquence before Brukinsa for MCL; trial of at least one anti‑CD20 regimen for certain MZL indications; combination use with obinutuzumab and two or more systemic therapies for FL where specified).prior therapy as specified per product

    See individual product entry for exact prior agents and combinations

    inv-04: Calquence — Mantle cell lymphoma (MCL)

    Covered when ONE of the following MCL-specific criteria is met:

    Calquence - relapsed/refractory MCL: Patient has mantle cell lymphoma and has received at least one prior therapy for MCL.

    Prior therapy must be documented

    Calquence - previously untreated and HSCT-ineligible: Previously untreated MCL in a patient who is ineligible for autologous hematopoietic stem cell transplant AND used in combination with bendamustine plus rituximab.

    Document ineligibility for HSCT and planned combination regimen

    inv-05: Cosentyx / related biologics — autoimmune indications

    Coverage for Cosentyx and similar biologics is provided when ALL of the following general rules are met and when the indication-specific prerequisites apply:

    Combination restriction and reauthorization: Agent is not used in combination with another biologic or targeted DMARD indicated for the same condition; reauthorization requires documentation of positive clinical response.

    Combination biologic use is excluded

    Indication-specific prerequisites: Coverage requires the diagnosis-specific criteria as applicable (examples: active psoriatic arthritis; moderate to severe chronic plaque psoriasis; ankylosing spondylitis with trial of at least one NSAID; non‑radiographic axial spondyloarthritis with objective inflammation and NSAID trial; enthesitis‑related arthritis with NSAID trial).

    Document diagnosis and prerequisite trials per indication

    inv-06: Dupixent — multiple indications

    Dupixent is covered when ALL of the applicable, indication-specific criteria below are met:

    Atopic dermatitis (AD): Diagnosis of moderate to severe atopic dermatitis AND trial and treatment failure of ONE of: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil.

    Age and weight limits apply per indication; document prior therapy

    Eosinophilic asthma (EA): Diagnosis of eosinophilic asthma AND eosinophil count >=150 cells/µL at initiation AND failure to maintain control after trial of systemic corticosteroids OR high‑dose inhaled corticosteroids plus trial of an additional controller (leukotriene modifier, LABA, or LAMA) in patients >=12 years.>=150 cells/µL

    Document eosinophil count and prior controller trials

    COPD add-on maintenance: Diagnosis of uncontrolled moderate to severe COPD AND eosinophil count >=300 cells/µL AND patient is currently receiving and will continue LABA, LAMA, and inhaled corticosteroid unless contraindicated.>=300 cells/µL

    Document eosinophil count and concurrent therapies

    Other indications and age/weight limits: Coverage for other labeled indications (e.g., EoE, PN, CRSwNP, CSU) requires meeting the age/weight restrictions and indication-specific prerequisite therapies listed in product labeling.

    See product entry for exact age/weight thresholds

    inv-07: Dalfampridine — multiple sclerosis

    Covered when ALL of the following are met:

    Dalfampridine initiation: Patient has multiple sclerosis, is ambulatory (not wheelchair bound), and a baseline timed 25‑foot walk (T25FW) test result is submitted prior to initiation.

    Requests excluded if patient is wheelchair bound

    Dalfampridine reauthorization: Reauthorization requires documentation of stability or improvement on the T25FW compared to baseline.

    Submit follow-up T25FW results

    inv-08: Epidiolex — seizure disorders

    Coverage for Epidiolex for seizure syndromes is provided when ANY of the following condition‑specific prerequisites are met:

    Lennox‑Gastaut syndrome: Diagnosis of Lennox‑Gastaut syndrome AND trial of two generic anticonvulsant alternatives for seizure treatment.

    Document prior anticonvulsant trials

    Dravet syndrome: Diagnosis of Dravet syndrome AND trial of two of: valproic acid, clobazam, or topiramate.

    Document selected prior agents and duration

    Tuberous sclerosis complex-associated seizures: Diagnosis of seizures associated with tuberous sclerosis complex AND trial of two generic anticonvulsant alternatives.

    Document prior anticonvulsant trials

    inv-09: Topiramate solution — migraine prevention and seizures

    Coverage is provided when ANY of the following criteria are met:

    Topiramate solution — migraine prevention: Indication for migraine prevention AND trial of at least two generic migraine preventive alternatives OR documented inability to swallow tablets/capsules.

    Document prior preventive trials or swallowing impairment

    Topiramate solution — seizure disorder: Indication for seizure disorder/epilepsy AND trial of at least two generic anticonvulsants OR documented inability to swallow tablets/capsules.

    Document prior anticonvulsant trials or swallowing impairment

    inv-10: Fintepla and similar anticonvulsant products - seizure indications

    Coverage for Fintepla and similar anticonvulsants is provided when ALL applicable step requirements are met:

    Fintepla seizure coverage: For Lennox‑Gastaut and related indications: trial of two generic anticonvulsant alternatives is required. For Dravet syndrome: trial of two of valproic acid, clobazam, or topiramate is required.

    Document prior therapy trials

    inv-11: Topiramate and migraine/seizure criteria

    Coverage is provided when ANY of the following prerequisite or step conditions are met:

    Topiramate — migraine or seizure: Preventive migraine: trial of at least two generic alternatives for migraine prevention OR inability to swallow tablets/capsules. Seizure disorder: trial of at least two generic anticonvulsants OR inability to swallow tablets/capsules.

    Document prior trials or swallowing inability

    inv-12: Fasenra — eosinophilic asthma and EGPA

    Covered when ALL applicable indication-specific criteria are met:

    Fasenra — eosinophilic asthma: Diagnosis of eosinophilic asthma with eosinophil count >=150 cells/µL at treatment initiation AND failure to maintain control after trial of systemic corticosteroids OR high‑dose inhaled corticosteroids plus trial of one additional controller (leukotriene modifier, LABA, or LAMA).>=150 cells/µL

    Reauthorization requires documentation of clinical response

    Fasenra — EGPA: Diagnosis of eosinophilic granulomatosis with polyangiitis AND history or presence of asthma AND at least two typical EGPA clinical criteria (e.g., histopathologic eosinophilic vasculitis, neuropathy, pulmonary infiltrates, nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, ANCA positivity).

    Document diagnostic criteria per labeling

    inv-13: Osteoporosis-related products

    Coverage is provided when ALL of the following are satisfied:

    Osteoporosis product criteria: Documented bone mineral density T‑score at or below -2.5 AND trial of both JUBBONTI or STOBOCLO AND either an oral bisphosphonate or, if intolerant, an IV bisphosphonate; coverage also allowed if patient is unable to be treated with all listed agents.T‑score <= -2.5

    Document BMD and prior therapy trials or contraindications

    inv-14: Fruzaqla — metastatic colorectal cancer

    Coverage is provided when ALL of the following are met:

    Fruzaqla — mCRC prerequisites: Metastatic colorectal cancer with prior trials of fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy AND prior anti‑VEGF therapy; for RAS wild‑type mCRC also requires trial of an anti‑EGFR therapy.

    Document prior chemotherapies and biologic therapy

    inv-15: Ibrance — HR+/HER2- advanced/metastatic breast cancer

    Coverage for Ibrance is provided when ANY of the following combination/sequence requirements are met:

    Ibrance — HR+/HER2- advanced/metastatic breast cancer: Use in combination with an aromatase inhibitor as initial endocrine‑based therapy OR in combination with fulvestrant for disease progression following endocrine therapy. For PIK3CA‑mutated disease, combination with inavolisib and fulvestrant is required after recurrence on or after completing adjuvant endocrine therapy.

    Document prior endocrine therapy and mutation status where applicable

    inv-16: Iclusig — CML and Ph+ ALL indications

    Coverage for Iclusig is provided when ANY of the indication- and sequencing-specific conditions below are met:

    Iclusig — Ph+ ALL (newly diagnosed): Newly diagnosed Ph+ ALL when used in combination with chemotherapy.

    Document combination chemotherapy plan

    Iclusig — T315I‑positive Ph+ ALL or CML: Monotherapy for T315I‑positive Ph+ ALL or for T315I‑positive CML (any phase) when no other kinase inhibitors are indicated.

    Document T315I mutation and rationale

    Iclusig — accelerated/blast phase CML: Accelerated or blast phase CML when no other kinase inhibitors are indicated.

    Document prior kinase inhibitor history

    Iclusig — chronic phase CML: Chronic phase CML indications require trial of at least two prior kinase inhibitors per product labeling.

    Document prior kinase inhibitor trials

    inv-17: Adalimumab products — rheumatologic and dermatologic indications

    Adalimumab products are covered when ALL applicable indication-specific prerequisites are met:

    Adalimumab — RA and related indications: RA: diagnosis of moderately to severely active RA AND trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine). Polyarticular JIA: diagnosis of active polyarticular JIA and trial of leflunomide or methotrexate. Ankylosing spondylitis: diagnosis of active AS and trial of an NSAID. Reauthorization requires documentation of positive clinical response. Concurrent combination use with another biologic/targeted DMARD for the same condition is prohibited.

    Document DMARD or NSAID trials and clinical response

    inv-18: Breast cancer — CDK4/6 or PI3K-related combination requirements

    Coverage for specified breast cancer regimens is provided when ALL combination or sequencing requirements are met:

    CDK4/6 or PI3K-related combination rules: HR‑positive, HER2‑negative advanced/metastatic breast cancer: combination with an aromatase inhibitor as initial endocrine therapy OR combination with fulvestrant after progression. Endocrine‑resistant, PIK3CA‑mutated disease: combination with inavolisib and fulvestrant following recurrence on or after adjuvant endocrine therapy.

    Document prior endocrine therapy and PIK3CA mutation status where applicable

    inv-19: Ph+ ALL and CML kinase inhibitor rules

    Coverage for Ph+ ALL and CML kinase inhibitors is provided when ALL of the following disease-status and prior-therapy conditions are met:

    Ph+ ALL / CML kinase inhibitor rules: Newly diagnosed Ph+ ALL: coverage requires combination with chemotherapy. T315I‑positive Ph+ ALL: monotherapy allowed when no other kinase inhibitors are indicated. T315I‑positive CML (any phase): coverage allowed. Accelerated or blast phase CML: coverage when no other kinase inhibitors are indicated. Chronic phase CML: requires trial of at least two prior kinase inhibitors for other CP indications.

    Document mutation status and prior kinase inhibitor history

    inv-20: Biologic/targeted DMARD and RA/JIA/PMR requirements

    Coverage for biologic/targeted DMARDs in rheumatologic indications is provided when ALL of the following are met:

    RA/JIA/PMR biologic/DMARD prerequisites: Cannot be used in combination with another biologic or targeted DMARD indicated for the same condition; RA: diagnosis of moderately to severely active RA and trial of two listed agents (e.g., ENBREL, adalimumab biosimilars, Rinvoq, Xeljanz/XR, Orencia). PMR: history of corticosteroid treatment >10 mg/day prednisone equivalent for at least 8 weeks AND inadequate response or intolerance demonstrated by flare during taper >7.5 mg/day. Polyarticular JIA: diagnosis and trial of two listed agents. Reauthorization requires documentation of positive clinical response where specified.

    Document prior trials and exclude concurrent biologic use

    inv-21: Joenja — APDS specific requirements

    Joenja is covered when ALL of the following genetic and clinical criteria are met:

    Joenja — APDS coverage: 1) Diagnosis of APDS with associated PI3Kδ mutation, 2) documented variant in either PIK3CD or PIK3R1, AND 3) documented symptoms associated with APDS such as nodal/extranodal lymphoproliferation, recurrent oto‑sino‑pulmonary infections, or organ dysfunction (e.g., lung, liver).

    Genetic testing and clinical documentation required; cannot be used with an immunosuppressive medication for APDS

    inv-22: Lenvima (lenvatinib) — RCC and endometrial carcinoma criteria

    Lenvima is covered when ANY of the following combination or prior-therapy rules are satisfied for the listed indications:

    Lenvima — RCC and endometrial carcinoma: First‑line RCC: combination with pembrolizumab. RCC after anti‑angiogenic therapy: combination with everolimus after one prior anti‑angiogenic therapy. Advanced endometrial carcinoma: combination with pembrolizumab for disease progression following prior systemic therapy.

    Document prior therapy and planned combination

    inv-23: Formulation-specific coverage requirements

    Coverage for certain formulation‑specific products is provided when ALL of the following are met:

    Formulation-specific requirement — levetiracetam oral solution: Coverage requires BOTH: 1) trial of levetiracetam oral solution, AND 2) documented inability to swallow tablets or capsules.

    Both items must be documented

    Formulation-specific requirement — other products: For liquid formulations (e.g., Mekinist SOLR, Tafinlar liquid), coverage requires documented inability to swallow the standard tablet/capsule formulation and otherwise follows the tablet indication requirements.

    Document swallowing impairment and indication parity

    inv-24: Products requiring trial of levetiracetam oral solution and inability to swallow tablets/capsules

    Coverage requires BOTH of the following:

    Levetiracetam oral solution + swallow inability: 1) A trial of levetiracetam oral solution, AND 2) documentation that the patient is unable to swallow tablets or capsules.

    Applies to named product formulations requiring solution trial

    inv-25: Basal cell carcinoma (selected topical products)

    Coverage for selected basal cell carcinoma topical products is provided when ANY of the following are met:

    BCC prerequisite — Hedgehog pathway inhibitor: Prior treatment with a Hedgehog pathway inhibitor OR documentation that the patient is ineligible for Hedgehog pathway inhibitor treatment.

    Document prior Hedgehog inhibitor use or ineligibility

    inv-26: Liraglutide (diabetes indication) documentation requirement

    For the diabetes indication, coverage is provided when ONE of the following is met:

    T2DM documentation requirement: A) Medical records confirming a diagnosis of type 2 diabetes mellitus, OR B) laboratory evidence consistent with diabetes: A1c >= 6.5% OR fasting plasma glucose >= 126 mg/dL OR 2‑hour plasma glucose >= 200 mg/dL during OGTT.A1c >=6.5% or FPG >=126 mg/dL or 2‑hour PG >=200 mg/dL

    Exclude use for weight loss only

    inv-27: Lonsurf (metastatic colorectal and gastric cancers)

    Coverage for Lonsurf in metastatic colorectal (and selected gastric) cancer is provided when ALL of the following are met:

    Lonsurf — mCRC prerequisites: Combination use with bevacizumab AND prior trials of fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy AND prior anti‑VEGF therapy. For RAS wild‑type mCRC, also requires prior anti‑EGFR therapy where appropriate.

    Document prior chemotherapy lines and biologic therapy

    inv-28: Lumakras (KRAS G12C-mutated cancers)

    Coverage for Lumakras differs by tumor type and is provided when the following prior‑therapy conditions are met:

    Lumakras — NSCLC: KRAS G12C‑mutated locally advanced or metastatic NSCLC: requires trial of at least one prior systemic therapy.

    Document prior systemic therapy

    Lumakras — mCRC: KRAS G12C‑mutated metastatic colorectal cancer after prior fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy requires combination use with panitumumab.

    Document prior chemotherapies and combination plan

    inv-29: Lynparza (PARP inhibitor) oncology indications

    Lynparza coverage is provided when ALL applicable, indication‑specific prior therapy or condition requirements are met:

    Lynparza — ovarian cancer: Deleterious or suspected deleterious germline or somatic BRCA‑mutated advanced epithelial ovarian/fallopian tube/primary peritoneal cancer: requires prior platinum‑based chemotherapy; some indications require combination with bevacizumab per labeling.

    Document BRCA status and platinum response

    Lynparza — breast cancer: gBRCAm HER2‑negative metastatic breast cancer: requires prior chemotherapy in neo/adjuvant or metastatic setting; HR‑positive disease may require prior endocrine therapy as specified.

    Document prior chemo/endocrine therapy

    Lynparza — mCRPC HRR‑mutated: HRR gene‑mutated castration‑resistant prostate cancer: requires trial of enzalutamide or abiraterone per labeling.

    Document prior AR‑directed therapy

    inv-30: Mekinist (trametinib) — tablet and liquid formulations

    Mekinist coverage (tablet and liquid) is provided when ALL formulation- and indication-specific criteria are met:

    Mekinist tablets — labeled indications: Tablet formulation: coverage per labeled indications (e.g., monotherapy for BRAF‑inhibitor‑naive unresectable/metastatic melanoma with BRAF V600E/V600K detected by an FDA‑approved test) and combination use with dabrafenib or other BRAF combinations where required; prior trials of specified BRAF combinations may be required.

    Document mutation testing and prior combinations where applicable

    Mekinist liquid — swallow impairment: Liquid formulation: coverage requires documented inability to swallow tablets and otherwise follows the same mutation‑ and combination‑based requirements as the tablet formulation.

    Document inability to swallow and indication parity

    inv-31: Miscellaneous products with specific prior therapy requirements

    Coverage for miscellaneous products is provided when ALL listed product‑specific prior therapy or step requirements are satisfied:

    Motpoly XR (seizures): Coverage for seizures requires trial of two generic anticonvulsant alternatives prior to approval.

    Document prior anticonvulsant trials

    Other miscellaneous product examples: Apply product‑specific prior therapy rules as listed (e.g., Mavyret and other antiviral agents per current guidance).

    See individual product entries for details

    inv-32: Nucala — Indication-specific coverage criteria

    Nucala is covered when ALL applicable indication‑specific criteria are met (varies by sub‑indication):

    General Nucala rules: Cannot be used in combination with another biologic or targeted DMARD for the same condition; coverage duration 1 year; reauthorization requires documentation of positive clinical response.

    Document absence of combination biologic use and clinical response

    Nucala — eosinophilic asthma (EA): Diagnosis of eosinophilic asthma with eosinophil count >=150 cells/µL at initiation AND failure to maintain control after trial of systemic corticosteroids OR high‑dose inhaled corticosteroids plus trial of an additional controller (leukotriene modifier, LABA, or LAMA).>=150 cells/µL

    Document eosinophil count and prior controller trials

    Nucala — EGPA: Diagnosis of EGPA AND at least two typical EGPA criteria (e.g., histopathologic eosinophilic vasculitis, neuropathy, pulmonary infiltrates, nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, ANCA positivity).

    Document diagnostic criteria

    Nucala — HES: Diagnosis of HES AND eosinophil count >=1000 cells/µL at initiation AND stability on HES therapy (e.g., oral corticosteroids, immunosuppressive or cytotoxic therapy).>=1000 cells/µL

    Document eosinophil count and stability on therapy

    Nucala — COPD/CRSwNP: CRSwNP: diagnosis and recurring CRSwNP despite intranasal corticosteroids. COPD: diagnosis of uncontrolled moderate to severe COPD and either current eosinophil >=150 cells/µL OR eosinophil >=300 cells/µL within past 12 months plus ongoing LABA+LAMA+ICS use unless contraindicated.>=150 or >=300 cells/µL

    Document eosinophil counts and concurrent inhaled therapy

    inv-33: Praluent initial and reauthorization

    Praluent is covered when ALL of the following initial and reauthorization criteria are satisfied:

    Praluent — diagnostic and statin requirements (initial): Diagnosis consistent with labeled indications (e.g., ASCVD, HeFH, primary hyperlipidemia) AND LDL values while on a high‑intensity statin within the last 120 days meeting thresholds (LDL >=55 mg/dL with ASCVD OR LDL >70 mg/dL without ASCVD) AND trial of at least 12 weeks of high‑intensity statin unless statin intolerance is documented.LDL >=55 mg/dL w/ ASCVD OR LDL >70 mg/dL w/o ASCVD

    Document LDL on high‑intensity statin and statin trial or intolerance

    Praluent — reauthorization: Reauthorization (HeFH/ASCVD/Primary HLD) requires continuation of statin at maximum tolerated dose (unless documented inability) and evidence of LDL reduction on Praluent; coverage duration = 3 years.

    Document ongoing statin therapy and LDL response

    inv-40: Eltrombopag

    Eltrombopag is covered when ANY of the following baseline platelet and condition‑specific criteria are met:

    Eltrombopag — ITP and related indications: Persistent or chronic immune thrombocytopenia (ITP): baseline platelet count <30,000/mcL AND trial of corticosteroids, immunoglobulins, or splenectomy as indicated. Thrombocytopenia with chronic hepatitis C: baseline platelet count <75,000/mcL. Severe aplastic anemia: baseline platelet count <30,000/mcL.

    Document baseline platelet counts and prior interventions

    inv-41: Piqray

    Piqray (alpelisib) is covered when ALL of the following are met:

    Piqray coverage: Adult patients with HR‑positive, HER2‑negative, PIK3CA‑mutated advanced or metastatic breast cancer who have progressed on or after an endocrine‑based regimen and who will receive combination therapy with fulvestrant.

    Document PIK3CA mutation and prior endocrine progression

    inv-42: Retevmo: RET-altered cancers

    Retevmo is covered when ALL applicable genetic and prior therapy requirements are met for RET‑altered cancers:

    Retevmo — RET fusion NSCLC: Adult patients with locally advanced or metastatic NSCLC with RET gene fusion detected by an FDA‑approved test.

    Document RET fusion by FDA‑approved test

    inv-43: Retevmo: thyroid and solid tumor requirements

    Additional Retevmo indications are covered when the following conditions are met:

    Retevmo — medullary/thyroid cancers: MTC with RET mutation and thyroid cancers with RET‑gene fusion (adult and pediatric >=2 years) when systemic therapy is required; some thyroid indications require trial and failure of radioactive iodine if appropriate.

    Document RET mutation/fusion and radioactive iodine trial status

    Retevmo — solid tumors: Locally advanced or metastatic solid tumors with RET‑gene fusion in patients who have progressed on or following prior systemic treatment.

    Document RET fusion and prior systemic therapy

    inv-44: Rubraca: genetic and prior therapy criteria

    Rubraca is covered when ALL applicable genetic and prior-therapy criteria are met:

    Rubraca — maintenance ovarian cancer: Maintenance treatment of adult patients with deleterious BRCA mutation‑associated recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer in complete or partial response to platinum‑based chemotherapy.

    Document deleterious BRCA mutation and platinum response

    Rubraca — mCRPC: Deleterious BRCA mutation‑associated metastatic castration‑resistant prostate cancer requires previous androgen receptor‑directed therapy.

    Document BRCA mutation and prior AR‑directed therapy

    inv-45: Rezdiffra: NASH/MASH with fibrosis

    Rezdiffra is covered when ALL of the following initial and renewal criteria are met:

    Rezdiffra — initial criteria: Diagnosis of noncirrhotic NASH or MASH with advanced liver fibrosis (stage F2–F3) verified by FibroScan or other imaging‑based non‑invasive assessment AND trial of semaglutide prior to initiation.F2 to F3

    Document fibrosis stage and semaglutide trial

    Rezdiffra — renewal criteria: Renewal requires one of: 1) NASH/MASH resolution and no worsening of fibrosis; 2) improvement in fibrosis by >=1 stage with no worsening of NASH/MASH or evidence the medication provides clinical benefit; 3) improvement or stabilization demonstrated by imaging or blood‑based non‑invasive assessment.>=1 stage improvement

    Document imaging or blood‑based evidence

    inv-46: Rinvoq: indication- and therapy-specific requirements

    Rinvoq (upadacitinib) is covered when ALL applicable indication‑ and therapy‑specific conditions are met:

    Rinvoq — RA: Diagnosis of moderately to severely active rheumatoid arthritis AND trial of one DMARD (e.g., methotrexate, leflunomide, sulfasalazine) as specified.

    Document DMARD trial

    Rinvoq — other autoimmune indications: PsA, AS, UC, CD, non‑radiographic axial SpA: diagnosis of active disease and for many indications inadequate response or intolerance to one or more TNF inhibitors or prior trial of an NSAID for axial disease as required.

    Document prior TNF inhibitor or NSAID trial where applicable

    Rinvoq — AD and combination restriction: Atopic dermatitis: diagnosis of moderate to severe AD and trial and failure of at least one listed therapy (high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil). For all indications reauthorization requires documentation of positive clinical response and that the patient is not receiving upadacitinib in combination with a potent immunosuppressant or another biologic/targeted DMARD for the same condition.

    Document prior topical/systemic therapy and absence of prohibited combinations

    inv-47: Rydapt: combination chemotherapy requirement

    Rydapt is covered when ALL of the following are met for FLT3‑mutated AML:

    Rydapt — newly diagnosed FLT3+ AML: Coverage for newly diagnosed FLT3‑mutation positive AML requires combination therapy with standard cytarabine and daunorubicin induction and cytarabine consolidation per labeled regimen.

    Document FLT3 mutation and planned combination chemotherapy

    inv-48: Tolvaptan: liver disease exclusion and prior treatment trial

    Tolvaptan is covered when ALL of the following documentation and prior‑treatment criteria are satisfied:

    Tolvaptan — liver disease exclusion and prior treatments: Documentation that the patient does NOT have underlying liver disease AND trial of at least two of: furosemide, demeclocycline, or fluid restriction prior to initiation.

    Document absence of liver disease and trials of alternative therapies

    inv-49: Sapropterin: initial response requirement

    Sapropterin initial authorization is provided when ALL of the following are met:

    Sapropterin — initial response requirement: Initial authorization granted for 2 months; extension to one year requires documented clinical response after the initial therapy period. Renewal requires documented improvement after initial 2 months.2 months initial trial

    Document response during initial authorization period

    inv-50: Sarclisa: prior therapy requirements

    Sarclisa is covered when ANY of the following prior‑therapy requirements are met for multiple myeloma indications:

    Sarclisa — multiple myeloma prior therapies: Coverage for multiple myeloma requires treatment with at least two prior therapies including lenalidomide and a proteasome inhibitor; relapsed/refractory myeloma requires 1–3 prior lines as specified; newly diagnosed ineligible for ASCT requires combination with bortezomib, lenalidomide and dexamethasone where indicated.

    Document prior lines of therapy and agents used

    inv-51: Scemblix: general listing

    Scemblix is listed with the following coverage note:

    Scemblix listing: Listed with coverage duration of 1 year; apply product labeling and prior‑therapy requirements where specified in the full product entry.

    Document applicable prior therapies per product label

    inv-52: Skyrizi: indication-specific requirements and combination restriction

    Skyrizi is covered when the indication‑specific criteria are met and the agent is not used in prohibited combinations:

    Skyrizi — indications: Coverage for psoriatic arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis requires the respective diagnosis and meeting indication‑specific prerequisites; reauthorization requires documentation of positive clinical response.

    Document diagnosis and clinical response

    Skyrizi — combination restriction: Cannot be used in combination with another biologic or targeted DMARD indicated for the same condition.

    Combination biologic use is excluded

    inv-53: Sohonos: genetic testing requirement

    Sohonos is covered when ALL of the following genetic confirmation requirements are met:

    Sohonos — FOP genetic testing: Coverage for fibrodysplasia ossificans progressiva (FOP) requires genetic testing confirmation showing an ACVR1 mutation.

    Submit genetic test confirming ACVR1 mutation

    inv-54: Skyrizi - Indication-specific criteria

    Skyrizi coverage (examples) — covered when ALL of the following apply:

    Skyrizi — example indication criteria: Coverage for psoriatic arthritis: diagnosis of active PsA; plaque psoriasis: diagnosis of chronic moderate to severe plaque psoriasis; Crohn's disease and ulcerative colitis: moderately to severely active disease. Reauthorization requires documentation of positive clinical response. Cannot be used in combination with another biologic/targeted DMARD for the same condition.1 year duration

    Document diagnosis, prior therapies, and clinical response

    inv-55: Tafinlar - Indication-specific criteria

    Tafinlar is covered when ALL applicable indication and formulation criteria are met:

    Tafinlar — melanoma and solid tumors: Unresectable or metastatic melanoma with BRAF V600E/V600K: trial of vemurafenib plus cobimetinib used in combination; for listed solid tumor indications, disease progression following prior treatment is required. Liquid formulation coverage requires documented inability to swallow capsules.1 year duration

    Document prior combination therapy and swallowing impairment where applicable

    inv-56: Tetrabenazine - Restrictions and testing

    Tetrabenazine coverage restrictions and testing requirements:

    Tetrabenazine exclusions and genotype testing: Not covered for patients with hepatic impairment, active suicidal ideation or untreated/inadequately treated depression, or concomitant use of MAO inhibitors or reserpine. Documentation of the patient's CYP2D6 genotype is required for doses above 50 mg per day.CYP2D6 testing for >50 mg/day

    Do not initiate in excluded populations; submit CYP2D6 genotype when applicable

    inv-57: Tagrisso - Indication-specific criteria

    Tagrisso is covered when ANY of the following indication‑specific scenarios are met:

    Tagrisso — EGFR mutation scenarios: EGFR exon 19 deletion or exon 21 L858R mutation‑positive NSCLC: use as adjuvant after resection, as first‑line in metastatic disease, or as first‑line in locally advanced/metastatic disease in combination with pemetrexed and platinum chemotherapy. EGFR T790M‑positive NSCLC: requires progression on or after an EGFR TKI.1 year duration

    Document mutation status and prior therapy where applicable

    inv-58: Tivdak

    Tivdak is covered when ALL product-specific requirements are met per labeling:

    Tivdak coverage: Coverage duration one year; apply indication‑specific prior therapy requirements (e.g., previous treatment for cholangiocarcinoma) as specified in the product entry.

    Document prior therapies per indication

    inv-59: Tocilizumab

    Tocilizumab is covered when ALL of the following broad and indication‑specific criteria are met:

    Tocilizumab general rules: Indication is medically accepted AND not used in combination with another biologic or targeted DMARD indicated for the same condition; reauthorization requires documentation of positive clinical response.

    Document diagnosis and absence of prohibited combination therapy

    Tocilizumab — RA and JIA prior therapy: RA and polyarticular JIA: diagnosis and trial of two of the following prior therapies: ENBREL, adalimumab biosimilars, RINVOQ, XELJANZ/XR, ORENCIA. SJIA: trial of one of NSAID, systemic glucocorticoid, or methotrexate as specified.

    Document prior DMARD/NSAID/glucocorticoid trials

    Tocilizumab — GCA: Diagnosis of giant cell arteritis (GCA) where indicated per labeling.

    Document diagnostic confirmation

    inv-60: Trodelvy

    Trodelvy is covered when ALL of the following are met:

    Trodelvy general criteria: Coverage duration one year; unresectable locally advanced or metastatic triple‑negative breast cancer requires prior use of two or more systemic therapies (at least one for metastatic disease). For HR+/HER2‑ disease, requires prior endocrine‑based therapy and at least two additional systemic therapies in the metastatic setting.

    Document prior systemic therapies

    inv-61: Voquezna Dual/Triple Pak (H. pylori)

    Voquezna (Dual/Triple Pak) for H. pylori is covered when ALL of the following are met:

    Voquezna — H. pylori regimen requirement: Diagnosis of H. pylori infection AND trial of a guideline‑recommended generic first‑line regimen (e.g., clarithromycin triple therapy or bismuth quadruple therapy) unless contraindicated; document prior first‑line regimen use.

    Document prior first‑line regimen trial or contraindication

    inv-62: Tymlos

    Tymlos is covered when ALL of the following are met:

    Tymlos criteria: Documentation of bone mineral density T‑score <= -2.5 AND trial of both JUBBONTI or STOBOCLO AND either an oral bisphosphonate or, if intolerant, an IV bisphosphonate; coverage duration two years.T‑score <= -2.5

    Document BMD and prior therapy trials or contraindications

    inv-63: Verquvo

    Verquvo is covered when ALL of the following clinical criteria are satisfied:

    Verquvo criteria: Diagnosis of chronic heart failure NYHA class II‑IV with LVEF <45% AND one of: prior hospitalization for heart failure within 6 months OR outpatient IV diuretic treatment within 3 months; therapy must be taken in combination with at least two specified standard heart failure therapies unless contraindicated or not tolerated.LVEF <45%

    Document NYHA class, LVEF, hospitalization/IV diuretic history, and concurrent HF therapies

    inv-64: Verzenio

    Verzenio is covered when ALL product- and disease‑specific conditions are met:

    Verzenio criteria: Adjuvant HR+/HER2‑ node‑positive early breast cancer at high risk: combination with tamoxifen or an aromatase inhibitor. Advanced/metastatic settings: combination with endocrine agents as specified; monotherapy in metastatic setting requires prior endocrine and chemotherapy per labeling.

    Document prior endocrine/chemotherapy and combination plan

    inv-65: Other listed products (selected examples)

    Other listed specialty products are covered when ALL of their product‑specific criteria are met. Examples include:

    Vanflyta (FLT3‑ITD AML): Newly diagnosed FLT3‑ITD positive AML requires use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation; coverage duration one year.

    Document FLT3‑ITD status and combination regimen

    Venclexta (elderly/comorbid AML): Newly diagnosed AML in adults >=75 years or with comorbidities precluding intensive induction: requires combination with azacitidine, decitabine, or low‑dose cytarabine.

    Document suitability and chosen combination

    Pazopanib — STS: Advanced soft tissue sarcoma requires previous chemotherapy and prescription by an oncologist; coverage duration one year.

    Document prior chemotherapy and oncology prescribing

    inv-66: Example tumor indication (Vyndaqel/Vyndamax)

    Example tumor indication coverage (extracted example):

    Vyndaqel/Vyndamax — tumor indication example: Coverage provided for treatment of grade 2 astrocytoma or oligodendroglioma following surgery (biopsy, subtotal or gross total resection) per product labeling; coverage duration 1 year.

    Document surgical history and indication

    inv-67: Pazopanib—STSs

    Pazopanib for advanced soft tissue sarcoma is covered when ALL of the following are documented:

    Pazopanib — STS: Advanced soft tissue sarcoma requiring prior treatment with chemotherapy AND prescribed by an oncologist; coverage duration one year.

    Document prior chemotherapy and oncology prescriber

    inv-68: Voydeya—EVH with PNH

    Voydeya is covered when ALL of the following disease severity and combination requirements are met:

    Voydeya — EVH with PNH: Clinically significant extravascular hemolysis (EVH) with PNH: hemoglobin <= 9.5 g/dL AND absolute reticulocyte count >= 120 x10^9/L AND concurrent use only with Soliris or Ultomiris.Hgb <=9.5 g/dL; retic >=120 x10^9/L

    Document labs and concurrent complement inhibitor use

    inv-69: Xifaxan—indication-specific prerequisite therapy

    Xifaxan 550 mg coverage is provided when ALL indication‑specific prerequisite therapies are documented:

    Xifaxan 550 mg — HE/IBS‑D/C. diff prerequisites: Hepatic encephalopathy: trial of lactulose. IBS‑D: trial of loperamide, dicyclomine, or diphenoxylate/atropine. Recurrent C. diff: trial of vancomycin as specified. Document appropriate prior therapy trials.

    Document prior therapy trials per indication

    inv-70: Xolair—asthma/CSU/CRSwNP

    Xolair is covered when ALL applicable diagnostic and prior‑therapy criteria are met:

    Xolair — allergic asthma: Uncontrolled moderate to severe allergic asthma with positive skin test or in‑vitro reactivity to a perennial aeroallergen AND IgE levels within age‑appropriate ranges AND failure to maintain control after systemic corticosteroids or high‑dose inhaled corticosteroids plus trial of an additional controller (leukotriene modifier, LABA, or LAMA).IgE thresholds as specified

    Document IgE, allergy testing, and prior controller trials

    Xolair — CSU and CRSwNP: Chronic spontaneous urticaria: diagnosis with symptoms despite H1 antihistamine and trial of at least one second‑generation antihistamine. CRSwNP: recurrent CRSwNP despite intranasal corticosteroids. Reauthorization requires documentation of positive clinical response.

    Document antihistamine trial or intranasal steroid failure

    inv-71: Xeljanz—disease-specific criteria and combination exclusions

    Xeljanz (tofacitinib) is covered when ALL of the following disease‑specific and combination restrictions are met:

    Xeljanz — disease-specific prerequisites: Diagnosis of active disease for the labeled indication (RA, JIA, PsA, AS, UC) and trial of specified DMARDs or NSAIDs where required; for some indications, inadequate response or intolerance to one or more TNF inhibitors is required.

    Document prior DMARD/TNF inhibitor or NSAID trials

    Xeljanz — combination exclusion and reauthorization: Cannot be used in combination with a potent immunosuppressant (e.g., azathioprine, cyclosporine) or another biologic/targeted DMARD for the same condition; reauthorization requires documentation of positive clinical response.

    Document absence of prohibited combinations and clinical response

    inv-72: Xpovio—hematologic malignancy prior therapy requirements

    Xpovio is covered when ANY of the following prior‑therapy requirements for hematologic malignancies are satisfied:

    Xpovio — hematologic malignancy prior therapy: Multiple myeloma: failure of one prior therapy (or as specified); relapsed/refractory multiple myeloma: trial of at least four prior therapies for refractory disease. Relapsed/refractory DLBCL: trial of at least two lines of systemic therapy where indicated.

    Document prior lines of therapy and agents used

    inv-73: Zejula—maintenance therapy requirements

    Zejula maintenance coverage is provided when ALL of the following are met:

    Zejula — ovarian maintenance: Complete or partial response to first‑line platinum‑based chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer; coverage limited to 1 year for maintenance treatment.

    Document platinum response

    inv-74: Zepzelca—SCLC requirements

    Zepzelca is covered when ANY of the following SCLC criteria are satisfied:

    Zepzelca — metastatic SCLC: Metastatic small cell lung cancer with disease progression on or after platinum‑based chemotherapy.

    Document prior platinum‑based chemotherapy and progression

    Zepzelca — maintenance extensive‑stage SCLC: Maintenance treatment of extensive‑stage SCLC in combination with atezolizumab (± hyaluronidase‑TQIS) and confirmation of no progression following first‑line induction with atezolizumab (± hyaluronidase‑TQIS), carboplatin and etoposide.

    Document induction regimen and no progression

    inv-77: Zilbrysq — Myasthenia gravis

    Zilbrysq for myasthenia gravis is covered when ALL of the following are met:

    Zilbrysq — diagnostic confirmation: Documentation of anti‑acetylcholine receptor (AChR) antibody positivity AND one confirmatory test (positive edrophonium test, history of clinical response to oral cholinesterase inhibitors e.g., pyridostigmine, OR electrophysiological evidence via RNS or SFEMG).

    Submit laboratory/confirmatory test evidence

    Zilbrysq — prior immunosuppressive therapy: Previous treatment courses of at least 12 weeks with one of: methotrexate, azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil, or tacrolimus unless contraindicated or not tolerated.

    Document prior immunosuppressive trial(s)

    Zilbrysq — exclusion and regimen stability: Patient must not have had thymectomy within 12 months, must not have current thymoma or other thymus neoplasms, and must be currently receiving and continue a stable regimen while on Zilbrysq; coverage duration 1 year.

    Document exclusions and stable regimen

    inv-78: Zonisade — Seizure disorder

    Zonisade is covered when ANY of the following are met:

    Zonisade — generic anticonvulsant trial: Trial of at least two generic anticonvulsants, one of which must be generic zonisamide.

    Document trials of two generics (including generic zonisamide)

    Zonisade — inability to swallow: Patient is unable to swallow tablets or capsules.

    Document inability to swallow

    inv-79: Zurzuvae — Postpartum depression

    Zurzuvae is covered when ALL of the following postpartum depression criteria are met:

    Zurzuvae — onset timing: Diagnosis of postpartum depression with onset of depressive symptoms in the third trimester or within 4 weeks postpartum.

    Document timing of symptom onset

    Zurzuvae — postpartum window: Member is currently <= 12 months postpartum.<= 12 months

    Document date of delivery

    Zurzuvae — coverage duration: Coverage duration limited to 60 days per policy provision.60 days

    Adbry (dupilumab) is not permitted to be used concurrently with any other biologic or targeted DMARD indicated for the same condition. This exclusion applies to initial requests and continuation; requests that propose combination use for the same diagnosis should be denied. (See product-specific PA requirements for age, prior therapy, and reauthorization documentation.)

    Certain biologic products are explicitly excluded from concomitant use with another biologic or targeted DMARD indicated for the same condition. Coverage for these agents is conditional on monotherapy (when indicated) and will be denied if documentation shows simultaneous treatment with another biologic/targeted DMARD for the same diagnosis.

    Tadalafil is not covered for members who are receiving concurrent nitrate therapy. Coverage determinations must exclude tadalafil use when nitrate therapy is present due to the contraindicated drug–drug interaction.

    Dalfampridine ER is excluded for patients who are wheelchair bound or who become wheelchair bound. Prior to initiation, a baseline timed 25-foot walk (T25FW) must be submitted; reauthorization requires documentation of stability or improvement on the T25FW.

    GLP‑1 receptor agonists are excluded when the sole purpose of treatment is weight loss. For coverage in type 2 diabetes, medical records or laboratory evidence (e.g., A1c ≥ 6.5%, FPG ≥ 126 mg/dL, or 2‑hour PG ≥ 200 mg/dL) must be provided; requests lacking documentation of diabetes will be denied as not medically necessary.

    Requests for the listed biologic and targeted DMARD agents will be denied if the therapy is being used in combination with another biologic or targeted DMARD indicated for the same condition. This combination restriction is applied across multiple autoimmune and inflammatory product entries and remains a basis for exclusion when concurrent same‑condition biologic therapy is documented.

    Step Therapy Requirements

    RequirementNotes / Examples
    Document prior trials
    Provider must include documentation of prior medication trials or failures when requesting authorization (e.g., Auvelity requires trial of bupropion + one other generic antidepressant).
    RequirementNotes / Examples
    Document prior therapy trials or combination use as specified
    For oncology and specialty agents, include prior therapy history or required combination regimens (e.g., Braftovi requires prior/combination use with vemurafenib + cobimetinib or cetuximab with fluorouracil-based chemotherapy for CRC).
    RequirementNotes / Examples
    Trial of 2 generic alternatives prior to coverage
    Seizure and migraine indications require documented trials of two generic alternatives (e.g., Lennox-Gastaut: 2 generic alternatives; migraine prevention: 2 generic alternatives) or documentation of inability to swallow tablets/capsules where allowed.
    RequirementNotes / Examples
    Step therapy requiring two triptans
    For certain acute migraine treatments, coverage requires trial of two formulary triptans: one oral and one non-oral (e.g., nasal or injectable) prior to approval; alternative triptan failure or contraindication should be documented.
    RequirementNotes / Examples
    Prior trials of specified generic alternatives, prior chemotherapies, or prior DMARDs as indicated per product
    Examples: Calquence (MCL) may require prior therapy or combination with bendamustine+rituximab; many biologics require trial of listed DMARDs before coverage and prohibit combination with another biologic/targeted DMARD. Document the specific prior agents and durations per product entry.
    RequirementNotes / Examples
    Step or trial of prior therapies required for coverage in multiple listed indications
    Many oncology and specialty indications require documented prior lines or classes of therapy (e.g., newly diagnosed Ph+ ALL requires combination with chemotherapy; Trodelvy for TNBC requires prior use of two or more systemic therapies).
    RequirementNotes / Examples
    Step therapy requires documentation of trials of listed prior therapies before coverage is granted
    Examples include prior platinum-based chemotherapy for Lynparza indications and required prior systemic therapies or anti-VEGF/anti‑EGFR therapy for certain metastatic colorectal cancer regimens — document prior agents and responses.
    RequirementNotes / Examples
    Must have failed two generics prior to approval
    For specific seizure products (e.g., Motpoly XR) and other anticonvulsants, coverage requires documentation of failure or intolerance to two generic anticonvulsant alternatives prior to approval.
    RequirementNotes / Examples
    Statin trial required prior to Nexletol/Nexlizet
    Coverage requires trial of one high-intensity statin for at least 12 weeks unless the patient has documented intolerance or contraindication; Praluent (alirocumab) has LDL thresholds and documents statin use while on high-intensity statin within the last 120 days.
    RequirementNotes / Examples
    Bromocriptine trial required
    Octreotide for acromegaly requires documentation of a trial of bromocriptine mesylate at maximally tolerated doses prior to approval. Document dose and response.
    RequirementNotes / Examples
    Trial of two alternative azoles required before posaconazole approval
    Posaconazole DR for prophylaxis or treatment requires documented trial of two of: fluconazole, itraconazole, or voriconazole before approval; indicate which agents were tried and reasons if not tolerated.
    RequirementNotes / Examples
    Trial of at least 12 weeks of high-intensity statin before Praluent initiation
    Initial Praluent approval requires LDL values while on high-intensity statin within the last 120 days meeting thresholds (LDL >=55 mg/dL with ASCVD or LDL >70 mg/dL without ASCVD) and documentation of at least 12 weeks of high-intensity statin unless statin intolerance is documented.
    RequirementNotes / Examples
    Coverage for advanced GIST requires prior therapy with 3+ kinase inhibitors
    Document prior therapy with three or more kinase inhibitors including imatinib for advanced gastrointestinal stromal tumor as a condition of coverage. Provide agent names and treatment durations.
    RequirementNotes / Examples
    Rezdiffra requires trial of semaglutide prior to coverage
    For NASH/MASH with stage F2–F3 fibrosis, prior trial of semaglutide must be documented before Rezdiffra initiation; include fibrosis assessment method (e.g., FibroScan) and response criteria for renewal.
    RequirementNotes / Examples
    Retevmo requires prior systemic therapy for certain indications
    Retevmo coverage for locally advanced/metastatic solid tumors with RET fusion is provided for patients who have progressed on or following prior systemic treatment; some thyroid indications require trial and failure with radioactive iodine when appropriate — document prior systemic therapies or radioactive iodine trial/failure.
    RequirementNotes / Examples
    Examples where step therapy is required (collection)
    Examples: Spritam and several anticonvulsants require trials of two generic anticonvulsants; some antidepressants require trials of listed generic agents; Sunosi requires trial of armodafinil. Include specific product-level step requirements when submitting PA. (See product entries.)
    RequirementNotes / Examples
    Many products require prior trials or combination therapy (oncology examples)
    Oncology examples: Trodelvy requires two or more prior systemic therapies for TNBC; Lonsurf/mCRC requires combination with bevacizumab and prior fluoropyrimidine-/oxaliplatin-/irinotecan-based chemotherapy; Verquvo requires prior standard heart failure therapies. Document prior regimens and responses.
    RequirementNotes / Examples
    Trial and failure of specified agents prior to coverage
    Many agents require documented failure of specified prior therapies (e.g., Xpovio/multiple myeloma requires prior therapies; Xifaxan HE requires trial of lactulose). Provide prior agent names, durations, and reasons for discontinuation.
    RequirementNotes / Examples
    Trials of specified oral/generic alternatives required prior to coverage (lists provided per product)
    Psychiatric and other agents require trials of listed generic alternatives (e.g., Exxua/Trintellix: two listed generic antidepressants; antipsychotics require trial of at least one listed generic antipsychotic). Include documentation of the specific generics tried and outcomes.
    RequirementNotes / Examples
    Trial of at least one listed generic antipsychotic prior to approval
    Coverage for long‑acting injectable antipsychotics (e.g., Abilify Maintena, Aristada-related products) requires documentation of trial (or intolerance) of at least one listed generic antipsychotic agent. Document agent, dose, and intolerance or lack of efficacy.
    RequirementNotes / Examples
    Prior use of specified paliperidone palmitate formulations for defined durations
    Invega Hafyera requires prior use of 1‑month paliperidone palmitate for at least 4 months OR the 3‑month formulation for at least one three‑month cycle; include dates and formulations used. Coverage duration typically lifetime once requirement met.
    RequirementNotes / Examples
    Trial of generic dapagliflozin required prior to coverage for Farxiga and Jardiance; exception noted
    Document trial of generic dapagliflozin for Farxiga and Jardiance requests. Exception: step therapy does not apply to Jardiance when used to reduce risk of cardiovascular death in adults with T2DM and established cardiovascular disease — document indication.
    RequirementNotes / Examples
    Trial of a generic formulary ophthalmic glaucoma medication or Lumigan required prior to coverage for Rhopressa and Rocklatan
    Prior authorization for Rhopressa and Rocklatan requires documentation of trial of any generic formulary ophthalmic glaucoma medication or latanoprost (Lumigan); include agent names and treatment dates. Coverage duration typically 1 year.
    RequirementNotes / Examples
    Trial of specified generic or oral alternatives (collection)
    Examples: Risperidone ER/Rykindo require trial of oral risperidone; Rytary requires trial of generic ER carbidopa/levodopa; Febuxostat requires trial or contraindication to allopurinol; Rasuvo requires trial of generic injectable methotrexate. Provide prior agents, durations, and reasons for failure/intolerance.

    Provider Actions & Documentation Requirements

    Prior Authorization

    PA required for listed formulary drugs

    Prior authorization is required for drugs listed in the formulary and must be obtained before coverage; PA may require meeting clinical and/or administrative criteria and is typically granted for one year unless otherwise specified.

    • Submit required medical records and evidence of prerequisite therapy trials where applicable.
    • Confirm coverage duration (commonly 1 year) and any product‑specific documentation or lab thresholds prior to submission.
    Prior Authorization

    Adbry PA and prerequisite therapy

    Adbry requires prior authorization and a documented trial and treatment failure of one of the listed topical or systemic therapies for atopic dermatitis in patients 12 years and older; reauthorization requires documentation of a positive clinical response and dosing for patients <100 kg is limited to 300 mg every 4 weeks after 16 weeks unless clinical rationale is provided.

    • Trial and failure of one: high‑potency topical corticosteroid, tacrolimus, pimecrolimus, cyclosporine, azathioprine, or mycophenolate mofetil.
    • Do not request Adbry in combination with another biologic or targeted DMARD for the same condition.
    Prior Authorization

    General prior authorization requirement

    Obtain prior authorization with required clinical documentation (diagnosis, prerequisite therapy trials when specified) — most authorizations are for one year; some products may require initial shorter durations or lifetime coverage as noted per product.

    • Include diagnosis, prior therapy trial dates, relevant labs/imaging, and prescriber information.
    • Verify product-specific duration (e.g., Praluent = 3 years; many biologics = 1 year).
    Documentation Required

    Reauthorization requires documentation of clinical response

    For biologics and many specialty agents, reauthorization requires documentation that the patient has experienced a positive clinical response to therapy; include objective measures or clinician assessment in the request.

    • Attach clinical notes demonstrating improvement or stability per the product’s reauthorization criteria.
    • For Nucala and similar agents, explicitly state the clinical benefit observed since initiation.
    Prior Authorization

    PA: include diagnosis, prior trials and duration

    Prior authorization requests must include diagnosis, documentation of required prior therapy trials where specified, and supporting labs or imaging; coverage durations are typically one year unless a different duration is specified.

    • For drugs with lab thresholds (e.g., eosinophil counts, LDL, BMD), include the corresponding lab values and dates.
    • If a prerequisite Part D drug is required, document the trial and dates in the chart or claim history.
    Prior Authorization

    Breast cancer: document required combination therapy

    For HR‑positive, HER2‑negative advanced/metastatic breast cancer, ensure PA documents combination use with an aromatase inhibitor as initial endocrine‑based therapy or with fulvestrant after progression; include prior endocrine therapy history.

    • Document regimen (aromatase inhibitor or fulvestrant) and prior endocrine therapy status.
    • Include tumor receptor status and relevant prior treatment dates.
    Prior Authorization

    Ph+ ALL: combination with chemotherapy or mutation‑driven monotherapy

    For newly diagnosed Ph+ ALL, submit prior authorization showing combination use with chemotherapy; for T315I‑positive Ph+ ALL or CML monotherapy may be allowed when no other kinase inhibitors are indicated — document mutation status and prior kinase inhibitor history.

    • Provide cytogenetic/mutation testing results (T315I) and chemotherapy regimen details.
    • If monotherapy requested, document absence of alternative indicated kinase inhibitors.
    Prior Authorization

    Lenvima: include combination and prior therapy details

    When requesting Lenvima, include documentation of the required combination partner or prior therapy per indication (e.g., combination with pembrolizumab for first‑line RCC); specify tumor type and prior systemic therapies.

    • Document prior lines of therapy and rationale for chosen combination.
    • Include oncology treatment history and dates.
    Documentation Required

    Formulation requirement: levetiracetam solution plus swallow impairment

    For formulation‑specific requests (e.g., levetiracetam oral solution), provide BOTH a trial of the oral solution and objective documentation that the patient is unable to swallow tablets or capsules.

    • Document trial of levetiracetam oral solution and evidence of swallowing impairment (e.g., clinician note).
    • If requesting an alternative formulation, show why tablets/capsules are not feasible.
    Documentation Required

    Liquid formulation: document inability to swallow and same indication criteria

    Liquid formulations (e.g., Mekinist liquid) require documented inability to swallow tablets and otherwise meet the same mutation‑ and combination‑based indication requirements as the tablet formulation.

    • Provide evidence of swallowing impairment and the same molecular testing or prior therapy documentation required for tablet use.
    • Confirm the indication and any combination therapy specified for the tablet form.
    Prior Authorization

    mCRC: document required combination use and prior chemotherapies

    For Lonsurf in mCRC, prior authorization must document combination use with bevacizumab and prior chemotherapy history including fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based regimens and anti‑VEGF therapy; for RAS wild‑type disease document prior anti‑EGFR therapy trial.

    • Attach prior chemotherapy regimen details and dates, and confirmation of bevacizumab combination.
    • For RAS wild‑type mCRC, include prior anti‑EGFR therapy trial documentation.
    Prior Authorization

    Age‑restricted prior authorization — confirm patient age

    Certain prior authorizations apply only for patients under age 30 — confirm patient age and include it in the PA request when the product entry specifies this restriction.

    • Verify patient date of birth and include age in the PA submission.
    • If age restriction applies, document rationale if requesting an exception.
    Prior Authorization

    Nucala: include eosinophil counts, diagnosis and prior controller trials

    Nucala PA requires indication‑specific documentation (e.g., eosinophil counts, diagnosis confirmation, prior controller therapy trials); reauthorization requires documentation of positive clinical response.

    • Include eosinophil count at initiation (≥150 cells/µL for eosinophilic asthma; ≥300 cells/µL for COPD add‑on maintenance where applicable).
    • Provide evidence of prior controller therapies and clinical response for reauthorization.
    Documentation Required

    GAA deficiency drugs: diagnostic assay and genetic confirmation

    Drugs for enzyme deficiency (GAA/Pompe) require PA with documentation of diagnostic confirmation by serum assay showing decreased acid alpha‑glucosidase activity and genetic testing demonstrating a GAA mutation; include symptom documentation and history of ERT response.

    • Attach serum assay results showing decreased enzyme activity and genetic testing confirming a GAA mutation.
    • Document symptomatic manifestations and lack of improvement on current ERT.
    Prior Authorization

    Posaconazole DR: document prior azole trials and high‑risk status

    Posaconazole DR prior authorization for prophylaxis or treatment requires documentation of high‑risk status or prior fungal infection and trials of two alternative azoles (fluconazole, itraconazole, or voriconazole); coverage duration is 6 months for prophylaxis.

    • Include prior azole trial dates and responses.
    • For prophylaxis, document HSCT/GVHD status or prolonged neutropenia indication.
    Documentation Required

    Praluent: document high‑intensity statin trial and LDL lab values

    Praluent PA requires documentation of LDL values while on a high‑intensity statin within the last 120 days and a trial of at least 12 weeks on high‑intensity statin (or documented statin intolerance); reauthorization requires continued statin therapy (or intolerance) and evidence of LDL reduction.

    • Provide LDL while on high‑intensity statin (LDL ≥55 mg/dL with ASCVD or LDL >70 mg/dL without ASCVD).
    • Document statin trial duration and any statin intolerance details.
    Billing Rule

    PA duration: verify and document product‑specific coverage length

    Most specialty PAs are granted for one year; verify product‑specific duration and include this in the PA request (some agents specify different durations such as 3 years or lifetime).

    • Check the product entry for coverage duration (e.g., Praluent = 3 years; many psychiatric long‑acting injectables = lifetime).
    • Plan requests and renewal timing accordingly.
    Documentation Required

    Retevmo: include RET genetic test and prior radioactive iodine when required

    Retevmo prior authorization requires documentation of RET gene fusion or RET mutation detected by an FDA‑approved test for RET‑altered cancers; some thyroid indications also require trial and failure with radioactive iodine where appropriate.

    • Attach the FDA‑approved test result documenting RET fusion/mutation.
    • When applicable, provide evidence of trial and failure with radioactive iodine.
    Documentation Required

    Tolvaptan: document absence of liver disease and prior treatments

    Tolvaptan PA requires documentation that the patient does not have underlying liver disease and evidence of trial of at least two alternative treatments (e.g., furosemide, demeclocycline, fluid restriction).

    • Include liver evaluation documenting absence of underlying liver disease.
    • Document trials of at least two listed alternative treatments and responses.
    Prior Authorization

    Skyrizi: 1‑year PA and reauthorization with clinical response; no combination biologics

    Skyrizi PA requires a 1‑year authorization and reauthorization must include documentation of positive clinical response; do not request Skyrizi in combination with another biologic or targeted DMARD for the same condition.

    • Provide diagnosis‑specific documentation (e.g., active PsA, plaque psoriasis, CD/UC activity) and clinical response for renewal.
    • Confirm absence of concurrent biologic/targeted DMARD therapy for the same condition.
    Prior Authorization

    Tafinlar: prior therapy and swallowability requirement for liquid

    Tafinlar (including liquid) requires prior authorization with 1‑year coverage; certain indications require prior therapies (e.g., vemurafenib + cobimetinib for BRAF V600E/V600K melanoma) and liquid formulation requests must document inability to swallow capsules.

    • Document prior BRAF‑targeted therapy trials and combination therapy history as required by indication.
    • For liquid formulation, include clinician documentation of swallowing impairment.
    Prior Authorization

    Tagrisso: PA with mutation and prior therapy documentation

    Tagrisso prior authorization requires 1‑year authorization and indication‑specific documentation (adjuvant after resection, first‑line metastatic, or EGFR T790M after progression on EGFR TKI); include mutation testing and prior EGFR TKI therapy when applicable.

    • Attach EGFR mutation testing results and prior therapy history.
    • State the treatment setting (adjuvant vs metastatic) and prior therapy outcomes.
    Prior Authorization

    PA required — follow product‑specific prerequisites and documentation

    Prior authorization is required for many specialty products; ensure the PA includes the product‑specific prerequisite therapies, diagnostic tests, and documentation outlined in the corresponding product entry.

    • Consult the product entry for required prior lines of therapy or combination partners.
    • Include all requested labs, imaging, genetic tests, and prior treatment documentation.
    Documentation Required

    Ovarian maintenance: document response to platinum chemotherapy

    Ovarian maintenance therapies require documentation of complete or partial response to first‑line platinum‑based chemotherapy before authorization; include chemotherapy regimen and response documentation.

    • Attach records confirming platinum‑based chemotherapy and response (CR/PR).
    • Include sequencing and dates of chemotherapy.
    Documentation Required

    SCLC: document progression after platinum chemotherapy; confirm induction status for maintenance

    For metastatic SCLC and maintenance extensive‑stage SCLC, document disease progression on or after platinum‑based chemotherapy; maintenance requests must confirm no progression following first‑line induction including atezolizumab when required.

    • Provide prior platinum‑based chemotherapy details and progression documentation.
    • For maintenance, document first‑line induction regimen and disease status post‑induction.
    Note
    Prior Authorization

    Zilbrysq MG: prior immunosuppressive therapy, antibody confirmation, and stable regimen

    Zilbrysq PA for myasthenia gravis requires prior treatment courses of at least 12 weeks with one of the listed immunosuppressive agents, documentation of anti‑AChR antibody positivity and one confirmatory test, and confirmation the patient will continue a stable regimen.

    • Include anti‑AChR antibody test result and one confirmatory test (edrophonium, response to cholinesterase inhibitors, or RNS/SFEMG).
    • Document prior 12‑week immunosuppressive therapy course and plan to continue stable regimen.
    Prior Authorization

    Zonisade seizure criteria: document generic anticonvulsant trials or swallow inability

    Zonisade PA requires either a trial of at least two generic anticonvulsants (one must be generic zonisamide) or documentation that the patient is unable to swallow tablets/capsules.

    • Document trials of two generic anticonvulsants (including generic zonisamide) with dates and outcomes.
    • If inability to swallow is claimed, include clinician documentation of swallowing impairment.
    Prior Authorization

    Zurzuvae PPD: onset timing and postpartum window documentation

    Zurzuvae PA for postpartum depression requires diagnosis with symptom onset in the third trimester or within 4 weeks postpartum and that the member is ≤12 months postpartum; include timing of symptom onset and postpartum status.

    • Document onset timing of depressive symptoms and the member’s postpartum age (≤12 months).
    • Include relevant psychiatric assessment and prior therapies if applicable.
    Denial Risk

    Combination biologic/targeted DMARD exclusion — confirm no concurrent biologic

    Requests for certain products will be denied if used in combination with another biologic or targeted DMARD indicated for the same condition; verify and document that no concurrent biologic/targeted DMARD for the same condition is being used.

    • Explicitly state concurrent medications and confirm absence of another biologic/targeted DMARD for the same condition.
    • If combination therapy is clinically justified, include rationale — but coverage is typically excluded.
    Denial Risk

    Drug‑drug exclusion: tadalafil with nitrates is not covered

    Do not submit PA requests for tadalafil when the patient is receiving nitrate therapy; such requests are not covered.

    • Confirm medication list for concurrent nitrate therapy and document in the PA request.
    • If nitrates are present, indicate that tadalafil should not be used per exclusion.
    Denial Risk

    Dalfampridine: wheelchair exclusion and T25FW documentation required

    Dalfampridine is excluded for patients who are wheelchair bound or become wheelchair bound — document ambulation status and include baseline timed 25‑foot walk (T25FW) prior to initiation; reauthorization requires stability or improvement on T25FW.

    • Submit baseline T25FW test results before initiation and include follow‑up T25FW for reauthorization.
    • Document patient ambulatory status; wheelchair‑bound patients are excluded.
    Denial Risk

    Weight‑loss exclusion: GLP‑1 agents not covered for weight‑loss only

    Requests for GLP‑1 receptor agonists used solely for weight loss (without documentation of T2DM) are excluded; when used for diabetes include medical records or lab evidence (A1c ≥6.5%, FPG ≥126 mg/dL, or 2‑hour PG ≥200 mg/dL).

    • For diabetes indication, attach A1c, FPG, or OGTT results demonstrating T2DM.
    • If obesity/weight‑loss use only, coverage will be denied.
    Denial Risk

    Posaconazole: document trial of two alternative azoles or risk denial

    Posaconazole prophylaxis requires documented trials of two alternative azoles (fluconazole, itraconazole, voriconazole); absence of these prior trials may lead to denial.

    • Provide dates and outcomes for trials of two listed azoles.
    • For treatment indications, include infectious disease specialist notes and culture/test results as appropriate.
    Documentation Required

    Invega Hafyera: document prior paliperidone palmitate LAI use for required durations

    Invega Hafyera authorization requires prior trial of 1‑month paliperidone palmitate for at least 4 months OR a 3‑month paliperidone palmitate cycle for at least one three‑month cycle; include prior long‑acting injectable history with dates.

    • Attach prior paliperidone palmitate long‑acting injectable administration records with durations.
    • If criteria not met, document clinical rationale or intolerance.
    Denial Risk

    Praluent: statin trial and LDL lab documentation required

    Praluent requests must show documented use of a high‑intensity statin for at least 12 weeks (or documented intolerance) and LDL values while on statin therapy; failure to document these will risk denial.

    • Include statin prescription history and LDL values within prior 120 days.
    • If statin intolerance claimed, provide supporting clinical documentation.
    Denial Risk

    Rivfloza: transplant and combination exclusions — verify history

    Rivfloza coverage is explicitly excluded for patients with a history of kidney or liver transplant or when used in combination with specified products (e.g., OXLUMO); verify transplant history and concurrent therapies.

    • Document transplant history (kidney or liver) — presence excludes coverage.
    • List current medications to confirm absence of excluded combination agents.
    Denial Risk

    Combination therapy exclusions with potent immunosuppressants or another biologic

    Do not request coverage when product entries prohibit combination with potent immunosuppressants or another biologic/targeted DMARD for the same condition (e.g., Rinvoq, Skyrizi, Xeljanz); such combinations may be denied.

    • Confirm and document current immunosuppressive and biologic therapies.
    • If combination is clinically necessary, include detailed justification though coverage is typically excluded.
    Denial Risk

    Tetrabenazine: exclusions and CYP2D6 genotype requirement for higher doses

    Tetrabenazine is not covered for patients with hepatic impairment, active suicidal ideation or untreated/inadequately treated depression, or concomitant use of MAO inhibitors or reserpine; for doses above 50 mg/day include CYP2D6 genotype documentation.

    • Document hepatic function, psychiatric status, and concomitant medications (MAO inhibitors, reserpine).
    • If dose >50 mg/day requested, include CYP2D6 genotype results.
    Documentation Required

    Tafinlar liquid: document inability to swallow capsule formulation

    Liquid Tafinlar requests must demonstrate inability to swallow capsules; include clinician documentation of swallow impairment when requesting the liquid formulation.

    • Provide objective evidence or clinician note documenting inability to swallow capsules.
    • Also include indication‑specific prior therapy documentation required for the capsule formulation.
    Prior Authorization

    H. pylori: document guideline‑recommended first‑line regimen trial

    For H. pylori therapies (Voquezna), document a trial of a guideline‑recommended, generic first‑line regimen (e.g., clarithromycin triple therapy or bismuth quadruple therapy); lack of such trial may result in denial.

    • Attach prescription records or clinician notes showing prior first‑line H. pylori regimen.
    • If regimen contraindicated, include rationale.
    Step Therapy

    Document trials of specified generics/alternatives to meet step requirements

    If a PA requires demonstration of prior generic or alternative therapy (e.g., oral risperidone before risperidone ER/Rykindo; generic ER carbidopa/levodopa before Rytary; generic dapagliflozin before Farxiga/Jardiance), include trial documentation or intolerance evidence to avoid denial.

    • Provide medication fill/claim history, dates, and reason for failure or intolerance.
    • For Jardiance CV indication, note that step therapy does not apply for the cardiovascular mortality indication.
    Billing Rule

    Claims history and site‑of‑care documentation (insulin lookback / Part B vs D)

    Ensure PA submissions include any required claims history (e.g., a claim for an insulin product within the last 180 days for certain gauze/pad products) and site‑of‑care information when needed to determine Medicare Part B vs Part D coverage.

    • Attach pharmacy/medical claims showing insulin product within 180 days when requested.
    • State the intended administration setting to determine Part B vs D coverage if relevant.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Coding, Lab Thresholds & Measurables

    Infusion/injectable product list (no CPT/HCPCS codes provided)mixed
    No codes listed
    inv-121: Eosinophil count (general)
    Eosinophil threshold (eosinophilic asthma)>= 150 cells per microliter at treatment initiation
    Eosinophil threshold (COPD add-on maintenance)>= 300 cells per microliter (current) OR >= 300 cells/µL within the past 12 months
    Eosinophil threshold (HES)>= 1000 cells per microliter at initiation
    Documentation requirementEosinophil counts must be submitted in medical records at initiation or per indication-specific timing
    inv-122: Timed walk (T25FW)
    Required testBaseline timed 25-foot walk (T25FW) must be submitted prior to initiation
    PurposeUsed for baseline eligibility and reauthorization documentation for dalfampridine in MS
    Reauthorization evidenceReauthorization requires documentation of stability or improvement on T25FW
    inv-123: Eosinophil count for eosinophilic asthma
    Initiation eosinophil threshold>= 150 cells per microliter at initiation of treatment
    Prior therapy requirementFailure to maintain control after systemic corticosteroids OR high-dose ICS plus an additional controller (leukotriene modifier, LABA, or LAMA)
    ReauthorizationReauthorization requires documentation of positive clinical response to therapy
    inv-124: Bone mineral density (BMD) T-score
    BMD T-score thresholdT-score at or below -2.5
    Required documentationBone mineral density report documenting T-score <= -2.5 must be submitted
    Prior therapy requirementTrial of specified agents (JUBBONTI or STOBOCLO) and either an oral bisphosphonate or IV bisphosphonate if intolerant
    inv-125: Diabetes diagnostic thresholds
    A1c diagnostic thresholdA1c >= 6.5%
    Fasting plasma glucose (FPG)FPG >= 126 mg/dL
    2-hour plasma glucose (OGTT)2-hour PG >= 200 mg/dL during OGTT
    inv-126: A1c, FPG, 2-hour PG thresholds
    A1c thresholdA1c >= 6.5%
    FPG thresholdFPG >= 126 mg/dL
    2-hour PG threshold2-hour PG >= 200 mg/dL during OGTT
    inv-127: Platinum therapy duration
    Referenced durationFirst-line platinum-based chemotherapy referenced as at least 6–16 weeks
    ContextUsed to document prior platinum exposure for ovarian/fallopian tube/primary peritoneal cancer maintenance eligibility
    DocumentationMedical records or chemotherapy administration records should confirm platinum-based regimen and timing
    inv-128: Eosinophil count (initiation)
    Initiation threshold (EA)>= 150 cells per microliter at treatment initiation for eosinophilic asthma
    COPD add-on maintenance threshold>= 300 cells per microliter (current) OR >=300 cells/µL within past 12 months plus ongoing LABA+LAMA+ICS
    EvidenceEosinophil count documentation must be included with prior controller therapy information
    inv-129: Eosinophil count for COPD criteria (alternative)
    Alternative COPD eosinophil threshold>= 300 cells per microliter within the past 12 months
    Concurrent therapy requirementPatient must be receiving and will continue LABA, LAMA, and inhaled corticosteroid unless contraindicated
    PurposeUsed to establish eligibility for add-on maintenance therapy in uncontrolled moderate to severe COPD
    inv-130: Eosinophil count for HES
    HES initiation threshold>= 1000 cells per microliter at initiation
    Additional requirementCoverage for HES requires diagnosis of HES and stability on HES therapy (e.g., oral corticosteroids, immunosuppressive or cytotoxic therapy)
    DocumentationSubmit eosinophil count at initiation and evidence of ongoing HES treatment
    inv-131: LDL thresholds for Praluent initiation
    LDL threshold with ASCVDLDL >= 55 mg/dL while on high-intensity statin (documented within last 120 days)
    LDL threshold without ASCVDLDL > 70 mg/dL while on high-intensity statin
    Statin trial/documentationDocumentation of at least 12 weeks of high-intensity statin (or documented intolerance) required
    inv-132: Eltrombopag baseline platelet counts
    ITP baseline platelet requirementBaseline platelet count < 30,000/mcL for persistent or chronic ITP
    Thrombocytopenia with chronic hepatitis CBaseline platelet count < 75,000/mcL
    Severe aplastic anemiaBaseline platelet count < 30,000/mcL
    inv-133: Tetrabenazine dose CYP2D6 testing threshold
    CYP2D6 genotype requirement thresholdCYP2D6 genotype documentation required for tetrabenazine doses above 50 mg per day
    Safety exclusionsTetrabenazine is not covered for patients with hepatic impairment or active suicidal ideation/untreated depression
    Contraindicated concomitant medsNot for use with MAO inhibitors or reserpine
    inv-134: Bone mineral density (T-score) for Tymlos
    Tymlos BMD thresholdBone mineral density T-score at or below -2.5 required
    Prior therapy requirementTrial of JUBBONTI or STOBOCLO and either an oral bisphosphonate (or IV bisphosphonate if intolerant) is required
    DocumentationSubmit BMD report showing T-score <= -2.5
    inv-135: Left ventricular ejection fraction (LVEF)
    LVEF thresholdLeft ventricular ejection fraction (LVEF) < 45% required
    NYHA class requirementDiagnosis of chronic heart failure NYHA class II–IV required
    Prior event requirementPlus prior hospitalization for heart failure within 6 months OR outpatient IV diuretic within 3 months
    inv-136: Hemoglobin / Absolute reticulocyte count (Voydeya)
    Hemoglobin threshold (Voydeya EVH with PNH)Hemoglobin <= 9.5 g/dL
    Absolute reticulocyte count thresholdAbsolute reticulocyte count >= 120 x 10^9/L
    Combination therapy requirementMust be used in combination with Soliris or Ultomiris only
    inv-137: IgE levels (Xolair)
    Allergic asthma IgE range (>=12 yrs)IgE > 30 and < 700 IU/mL for patients >= 12 years
    Allergic asthma IgE range (6–12 yrs)IgE > 30 and < 1300 IU/mL for patients 6 through 12 years
    CRSwNP IgE rangeIgE 30–1500 IU/mL at initiation for CRSwNP
    inv-138: Postpartum window for Zurzuvae
    Postpartum eligibility window (Zurzuvae)Member must be ≤ 12 months postpartum
    Onset timing requirementDiagnosis with onset in the third trimester or within 4 weeks postpartum (per Zurzuvae criteria)
    Coverage durationCoverage duration specified as 60 days for Zurzuvae when criteria met
    inv-139: Insulin claim lookback
    Insulin claim lookback periodClaim for an insulin product within the last 180 days required
    Applicable productsRequired for coverage of specified gauze/pad products tied to insulin use
    DocumentationSubmit claim history showing insulin product within 180 days

    Initial Therapy Criteria

    Continuation / Reauthorization Criteria

    Site of Care / Part B vs Part D Determination

    Note

    Infusion/administration setting may affect coverage (Part B vs D)

    For infusion products or drugs that may be billed under Medicare Part B or Part D, submit information describing the clinical use and site of care (infusion center, outpatient, or home) to determine the appropriate coverage pathway.

    Background & Scope

    The formulary prior authorization and step‑therapy criteria are developed from current medical evidence and the recommendations of the Blues' Pharmacy & Therapeutics Committee. These determinations are intended to ensure clinically appropriate, safe, and cost‑effective drug therapy for Medicare Plus Blue members; product entries specify coverage duration, prerequisite therapies, and documentation requirements.

    Definitions and Terms

    inv-285: Prior Authorization (PA)
    DefinitionA process where clinical and/or administrative criteria must be met before coverage of a drug is provided under the formulary.
    ApplicationRequired for listed formulary drugs identified with (PA); may include diagnosis, lab, prior therapy, and documentation requirements
    Typical durationCoverage durations commonly set to one year unless otherwise specified
    inv-286: Step Therapy (ST)
    DefinitionA requirement for prior treatment with one or more formulary drugs before coverage of the requested drug is allowed.
    PurposeUsed to promote use of clinically appropriate, lower-cost alternatives prior to specialty agents
    ExamplesApplies to numerous psychiatric, anticonvulsant, and other products requiring trials of generics or specific agents
    inv-287: Reauthorization
    DefinitionThe process requiring documentation of positive clinical response to therapy for continuation of coverage (reauthorization).
    DocumentationReauthorization commonly requires chart notes, objective test results, or other evidence of clinical benefit
    Common durationReauthorizations are typically annual; some products have lifetime duration after step criteria met
    inv-288: T25FW
    DefinitionTimed 25-foot walk (T25FW): baseline functional test required prior to initiation and for reauthorization of dalfampridine in MS.
    UseObjective measure of ambulatory function to document stability or improvement
    ReauthorizationRequires documentation of stability or improvement on T25FW
    inv-289: APDS
    DefinitionActivated Phosphoinositide 3-Kinase Delta Syndrome (APDS): genetic immunodeficiency associated with PIK3CD or PIK3R1 variants
    Coverage requirementJoenja coverage requires documented PI3Kδ mutation and associated clinical manifestations (lymphoproliferation, recurrent infections, organ dysfunction)
    Combination restrictionCannot be used in combination with an immunosuppressive medication for APDS
    inv-290: Platinum-based chemotherapy
    DefinitionPlatinum-based chemotherapy: chemotherapy regimens containing platinum agents used as prior therapy for ovarian/fallopian tube/primary peritoneal cancer prerequisites.
    DocumentationMedical records confirming prior platinum-based chemotherapy required for maintenance/eligibility in ovarian cancer indications
    Referenced duration/contextSome indications reference at least 6–16 weeks of platinum-based therapy as part of prior treatment history
    inv-291: BRAF V600E or V600K mutation
    DefinitionBRAF V600E or V600K mutation: genomic alteration detected by an FDA-approved test required for BRAF-targeted therapy coverage.
    DocumentationSubmit FDA‑approved test result confirming BRAF V600E or V600K mutation for indicated therapies
    ApplicationRequired for melanoma, NSCLC, anaplastic thyroid cancer, and other solid tumor BRAF-directed indications
    inv-292: EGPA definition
    DefinitionEGPA (Eosinophilic Granulomatosis with Polyangiitis): vasculitic syndrome requiring diagnosis plus ≥2 typical clinical criteria.
    Typical clinical criteriaExamples include histopathologic eosinophilic vasculitis, neuropathy, pulmonary infiltrates, nasal polyps, cardiomyopathy, glomerulonephritis, alveolar hemorrhage, palpable purpura, ANCA positivity
    DocumentationRequire diagnosis confirmation and documentation of at least two typical criteria for coverage
    inv-293: HES definition
    DefinitionHES (Hypereosinophilic Syndrome): diagnosis requiring eosinophil count >=1000 cells/µL at initiation and stability on HES therapy
    Treatment stabilityCoverage requires stability on HES therapy such as oral corticosteroids, immunosuppressive, or cytotoxic therapy
    DocumentationSubmit diagnostic and treatment records including eosinophil counts at initiation
    inv-294: Symptomatic manifestations (context)
    DefinitionSymptomatic manifestations: clinically significant symptoms required to support coverage for certain products (e.g., Opfolda).
    ExamplesProgressive muscle weakness, respiratory failure, frequent upper airway infections, orthopnea, sleep apnea, morning headaches (isolated cardiac hypertrophy not sufficient)
    DocumentationSubmit clinical exam findings, pulmonary function or other objective data supporting symptomatic disease
    inv-295: RET fusion / RET mutation
    DefinitionRET fusion / RET mutation: genomic alteration detectable by an FDA-approved test required for Retevmo eligibility.
    DocumentationSubmit FDA‑approved test result confirming RET fusion or RET mutation
    Indication-specific noteSome thyroid indications require trial and failure of radioactive iodine when appropriate
    inv-296: Deleterious BRCA mutation
    DefinitionDeleterious BRCA mutation: pathogenic BRCA alteration required for Rubraca maintenance eligibility
    DocumentationGenetic test confirming deleterious germline or somatic BRCA mutation required
    ContextRequired for maintenance treatment following response to platinum-based chemotherapy in ovarian-related cancers
    inv-297: Guideline-recommended first-line H. pylori regimens
    DefinitionGuideline-recommended first-line H. pylori regimens: examples include clarithromycin triple therapy (PPI+clarithromycin+amoxicillin or metronidazole) and bismuth quadruple therapy (PPI+bismuth+tetracycline+metronidazole)
    Prerequisite requirementCoverage for H. pylori treatment requires prior trial of a guideline‑recommended, generic first-line regimen unless contraindicated
    DocumentationSubmit documentation of prior first-line regimen or rationale for ineligibility
    inv-298: Anti-acetylcholine receptor (AChR) antibody positive MG
    DefinitionAnti-acetylcholine receptor (AChR) antibody positive MG: myasthenia gravis with lab‑confirmed anti‑AChR antibodies required for Zilbrysq coverage
    Confirmatory testingOne confirmatory test required: positive edrophonium test, history of response to cholinesterase inhibitors, or electrophysiologic evidence (RNS or SFEMG)
    ExclusionsPatients with thymectomy within 12 months, current thymoma, or other thymus neoplasms are excluded
    inv-299: Trial — definition
    DefinitionTrial: documented prior use of a medication for an adequate duration or documented intolerance to that medication required as a condition for authorization.
    PurposeUsed across step therapy and prior authorization rules to establish failure/intolerance to alternatives
    DocumentationMedical records, pharmacy claims, or chart notes acceptable to demonstrate trial or intolerance